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Background
The expression of catalytic phosphoinositol-3-kinase iso-
form δ (PI3Kδ) is restricted to the haematopoetic com-
partment. Accordingly, PI3Kδ serves as a drug target to
eliminate leukaemic cells. However, we previously
showed that PI3Kδ is indispensable for the function of
natural killer (NK)-cells [1]. Thus, the therapeutic suc-
cess of PI3Kδ inhibitors is likely to be compromised by
unintended side effects on the immune system. Besides
NK-cells, CD8
+ cytotoxic T-cells (CTLs) are well-known
key players in natural host response against developing
tumours and viral infections. In this study, we examine
t h er o l eo fP I 3 K δ for CTL function and CTL-mediated
tumour surveillance.
Methods
PI3Kδ
−/− animals have been described in [2]. Flow cyto-
metric lymphocyte characterization, the in vivo CTL-
assay and MC-38 tumour model were done as outlined
in [3]. Membrane capacitance and degranulation were
measured by patch-clamp recordings and flow cytometry,
respectively [1]; the mixed lymphocyte reaction was mon-
itored as in [4]. In vitro, expanded CTLs were generated
by stimulation with an anti-CD3ε antibody (0.5 µg/µL;
BDPharmingen) and cultured for 3 days in T-cell med-
ium containing 100 U/mL IL-2 prior to FACS analysis.
For the in vitro cytotoxicity assay mice were immunized
twice with the peptide SINFEKL. Peptide-reactive T-cells
were generated by co-culturing splenocytes derived from
immunized and control mice with SINFEKL-pulsed,
irradiated splenocytes for 5 days. Peptide-reactive T-cells
were co-cultured with CFSE-stained EL4 or EG7 cells in
different effector:target-ratios. After 18 h peptide-specific
killing was quantified via FACS.
Results
Antigen-specific cytotoxicity of PI3Kδ
−/− CTLs was sig-
nificantly reduced in vivo and in vitro as compared to
wild-type. This defect translated into severely impaired
CTL-mediated MC-38 tumour surveillance: tumours
derived from PI3Kδ
−/− recipients were significantly big-
ger. PI3Kδ was required for full activation of CTLs and
interfered with essential stages in the canonical killing
pathway of CTL, e.g. with the endowment of their lytic
machinery with key cytolytic molecules, with the pro-
duction of interferon-g and the fusion of lytic granules
with the cellular membrane.
Conclusions
Our findings are of particular interest for the clinical
development, because specific inhibitors of PI3Kδ are
entering clinical trials. Our observation shows that
PI3Kδ is indispensable for CTL effector functions.
Accordingly, long-term drug safety monitoring ought to
include adequate measures to identify side effects result-
ing from impaired surveillance of viral infections and
tumour cells.
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